olopatadine / Generic mfg. - LARVOL DELTA

Efficacy of 0.05% Cyclosporine Eye Drops in the Treatment of Allergic Conjunctivitis-Associated Dry Eye in Children (ChiCTR) - P4 | N=72 | Not yet recruiting | Sponsor: Beijing Childrens Hospital,Capital Medical University; Beijing Childrens Hospital,Capital Medical University

New P4 trial • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

A Clinical Study on the Effect of Topical Anti-Allergic Eye Drops on Skin Prick Test Results in Patients with Allergic Rhinoconjunctivitis (ChiCTR) - P=N/A | N=180 | Not yet recruiting | Sponsor: Meishan City Peoples Hospital; Meishan City Peoples Hospital

New trial • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Gland Pharma Limited (Gland)…has received approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) filed for olopatadine hydrochloride ophthalmic solution USP, 0.7% (OTC). (CNBC-TV18) - "It is indicated for the treatment of ocular itching associated with allergic conjunctivitis, offering patients an effective over-the-counter option for relief from allergy-related eye symptoms."

ANDA • Allergy • Ophthalmology

Temporarily induced facial eczema by IL-17 inhibitors: a case report and literature review. (PubMed, Front Allergy) - "After oral compound glycyrrhizin, olopatadine hydrochloride, triprolidine hydrochloride, and topical pimecrolimus for a week, his facial lesions were completely cleared. No recurrence of similar rash or other adverse effects was observed during the subsequent follow-up period over 5 months. It is concluded that eczema could be induced temporarily by secukinumab, and maybe continued application."

Journal • Alopecia • Atopic Dermatitis • Dermatology • Immunology • Psoriasis • Pyoderma Gangrenosum • Sarcoidosis • IL17A

Bioequivalence Study of Two Olopatadine Hydrochloride Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions. (PubMed, Clin Pharmacol Drug Dev) - "No serious adverse events occurred, and safety profiles were comparable between formulations. This research confirmed the bioequivalence and similar safety of the generic olopatadine hydrochloride tablets to the reference formulation."

Journal

Comparative analysis of the effectiveness of treatment for exudative otitis media and eustachitis associated with concomitant allergic rhinitis (PubMed, Vestn Otorinolaringol) - "To assess the comparative effectiveness of different AR therapy regimens and their impact on middle ear and Eustachian tube pathology, the 168 affected patients were divided into four parallel groups: Main group (41 patients): treated with a fixed-dose combination of mometasone furoate and olopatadine hydrochloride (Rialtris); Control group 1 (45 patients): received intranasal monotherapy with mometasone furoate; Control group 2 (41 patients): treated with the oral antihistamine levocetirizine; Control group 3 (41 patients): received combination therapy of intranasal mometasone furoate and oral levocetirizine. Due to the accelerated recovery of Eustachian tube function and restoration of its drainage capabilities, the need for invasive middle ear drainage procedures (e.g., shunting, tympanostomy) was eliminated in the group receiving the fixed intranasal combination of mometasone furoate and olopatadine hydrochloride. This fixed-dose combination appears to be the optimal..."

Journal • Allergic Rhinitis • Immunology • Inflammation • Otorhinolaryngology

Clinical Utility of Lacrimal Scintigraphy in the Management of Epiphora (EANM 2025) - "Of the patients with results discordant with the clinical symptoms, 8 % have undergone surgery and 21 % are awaiting surgery. The remaining 71 % have been managed medically using the following treatments: warm compression trial of lid taping lubrication botox punctal plugs olopatadine drops There were also plans for routine follow-up, including patients with discordant findings. Furthermore, the demonstration of level of abnormality in the scan played an important role in deciding the managemnet of the patient. In addition, the identification of abnormality in the asymptomatic eye may help in the early intervention and prevention of epiphora."

Clinical • Ophthalmology

Olopatadine vs. Rupatadine for Allergic Rhinitis: A Meta-Analysis of Randomized Controlled Trials. (PubMed, Cureus) - "Olopatadine showed greater efficacy in reducing symptoms of allergic rhinitis compared to rupatadine, while both drugs had similar safety profiles. These findings suggest that olopatadine may be preferred for more symptom relief, though larger trials are needed for further validation."

Journal • Retrospective data • Review • Allergic Rhinitis • Anesthesia • Immunology • Inflammation • Pain • Xerostomia

A case report of eruptive pruritic papular porokeratosis with atopic dermatitis treated with upadacitinib: a novel therapeutic perspective. (PubMed, Front Med (Lausanne)) - "Despite prior treatment with tofacitinib, acitretin, tripterygium glycosides, and antihistamines (epinastine and olopatadine), the patient exhibited a suboptimal clinical response. This case highlights the potential of upadacitinib as an effective and well-tolerated therapeutic option for eruptive pruritic papular porokeratosis with concurrent atopic dermatitis, particularly in refractory cases. Further studies are warranted to evaluate its long-term efficacy and safety."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Ophthalmology • Pruritus

Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta Analysis. (PubMed, Int Arch Allergy Immunol) - "Ebastine ranked first in the total symptom score(standardized mean difference(SMD) -2.80[95% confidence interval(CI):-5.12 to -0.47]) and pruritus score (SMD -1.10[95%CI: -2.06 to -0.13]), while olopatadine ranked first in the wheal score (SMD -0.84 [95%CI :-1.37 to -0.32]).Bepotastine besilate had a significantly lower incidence of somnolence in adverse events (odds ratio(OR) 0.15[95%CI: 0.03 to 0.69]) than other sgAHs. There are no meaningful differences in safety risks between different second-generation antihistamines. Keywords: second-generation antihistamines; Chronic urticaria; Total symptom score; Adverse events; Network meta-analysis."

Clinical • HEOR • Journal • Retrospective data • Review • Chronic Spontaneous Urticaria • Dermatology • Immunology • Pruritus • Urticaria

Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) (PRNewswire) - "Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC); compared to the active ingredient in Pataday Once Daily Relief."

Generic launch • Ophthalmology

Clinical Insights into Mometasone furoate/Olopatadine Combination Therapy (EAACI 2025) - "Sponsored By Menarini."

Clinical • Combination therapy • Allergic Rhinitis • Immunology

Onset of Action (OOA) and Efficacy of Azelastine Hydrochloride 0.15% Nasal Spray (AZNS) on Allergy Symptoms in an Environmental Exposure Chamber (EEC) Compared to Placebo (PL) and Mometasone Furoate/Olopatadine Hydrochloride NS (MFONS) (EAACI 2025) - "When post sensitivity analyses were performed to examine non-physiological responses (S1) and delayed assessments (S2), the OOA of AZNS for TNSS was even faster at 10 min (LS Means±SE: S1: -0.62±0.279, p-value=0.0274 and S2:-0.54±0.248, p-value=0.0321, respectively). Conclusion This study shows that a single dose of AZNS provides a non-steriodal alternative which provides fast relief of both nasal and ocular symptoms that is clinically meaningful and may lead to improved patient compliance and disease management."

Clinical • Allergy • Immunology

Occupational sensitisation to Chrysonilia sitophila in an asthmatic patient with nasal polyposis (EAACI 2025) - "The patient had a 20-year history of asthma and nasal polyposis (NP), treated with beclometasone dipropionate/formoterol fumarate, montelukast and mometasone furoate/olopatadine...Here, an interdisciplinary approach allowed identification of Cs as the culprit species in occupational mold exposure responsible for chronic respiratory diseases. Future perspectives include the development of diagnostic tests using Cs , information on the occupational risks of specific molds, and the development of appropriate prevention protocols."

Clinical • Allergy • Immunology

Drug-Related Visual Blurring: Findings from the U.S. Food and Drug Administration Adverse Event Reporting System Database. (PubMed, Eur J Pharmacol) - "Preventing drug-related vision issues is vital. Early risk assessment and intervention with personalized medication can reduce side effects, ensure safety, and improve quality of life."

Adverse events • Journal • Oncology • Ophthalmology • Retinal Disorders

Ranking the Efficacy of Topical Treatments for Ocular Allergy: A Network Meta-Analysis of Current Evidence. (PubMed, Ocul Surf) - "This network meta-analysis provides strong evidence supporting condition-specific treatment approaches in ocular allergies. Newer antihistamines, particularly Olopatadine, are most effective for mild-moderate conditions, while immunomodulators, especially Tacrolimus, show superior efficacy in severe cases. These findings provide clear evidence-based hierarchies for clinical decision-making in the management of different types of allergic conjunctivitis."

Journal • Retrospective data • Allergy • Conjunctivitis • Dry Eye Disease • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Stability and Efficacy of Mucoadhesive Eye Drops Containing Olopatadine HCl: Physicochemical, Functional, and Preclinical In Vivo Assessment. (PubMed, Pharmaceutics) - "In vivo, OCH-SH and OCH-HPG-SH drops provided prolonged antipruritic and analgesic effects compared to the reference product. Polysaccharide-based innovative formulations improve OCH retention, enhancing therapeutic efficacy and patient compliance in the treatment of allergic conjunctivitis."

Journal • Preclinical • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Pain

Direct-to-consumer customized nasal sprays for allergy relief: A market overview (COSM 2025) - "Both share three active ingredients: triamcinolone, ipratropium, and oxymetazoline, but differ in the antihistamine included—Allermi uses azelastine, while Nectar uses olopatadine. Allermi and Nectar are currently the only DTC sellers of customized allergy-relief IN sprays. Both emphasize convenience, transparent pricing, and customized spray formulations, with ongoing provider support. Nectar further positions the customized IN spray as a bridge to SLIT."

Allergy • Immunology

The therapeutic effect of IPL on children with refractory seasonal allergic conjunctivitis. (PubMed, BMC Ophthalmol) - "IPL therapy is effective in improving ocular surface symptoms in children with refractory seasonal allergic conjunctivitis, especially in suppressing eye itching, with good results."

Clinical • Journal • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

Application of machine learning assisted multi-variate UV spectrophotometric models augmented by kennard stone clustering algorithm for quantifying recently approved nasal spray combination of mometasone and olopatadine along with two genotoxic impurities: comprehensive sustainability assessment. (PubMed, BMC Chem) - "A comprehensive sustainability assessment employed six state-of-the-art tools, including the national environmental method index, complementary green analytical procedure index, analytical greenness metric, blue applicability grade index, carbon footprint analysis, and the red-green-blue 12 metrics. Favorable results across all metrics affirmed the method's eco-friendliness, real-world applicability, and cost-effectiveness, supporting sustainable development goals in pharmaceutical quality control processes."

Journal

Treatment of allergic rhinitis and allergic conjunctivitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Comparison table: Some nasal sprays for seasonal allergic rhinitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Immunology • Inflammation

Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) (PRNewswire) - "Glenmark Pharmaceuticals Inc...has received final approval by the United States Food & Drug Administration (U.S. FDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), determined by the FDA to be bioequivalent to Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), of Alcon Laboratories, Inc. Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the U.S. by Glenmark Therapeutics Inc., USA."

ANDA • Ophthalmology

Comparative assessment of alcaftadine and olopatadine for allergic conjunctivitis: a meta-analysis. (PubMed, Postepy Dermatol Alergol) - "These two groups had similar incidence of adverse events (OR = 0.61; 95% CI = 0.34 to 1.09; p = 0.10). Alcaftadine had better capability to treat allergic conjunctivitis compared to olopatadine."

Journal • Retrospective data • Review • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Comparing the effectiveness of four antihistamines with olopatadine in healthy Thoroughbred horses. (PubMed, J Vet Med Sci) - "The maximum wheal inhibition rate (mean ± SD) of olopatadine (85.3% ± 7.7%) was significantly higher than those of bilastine (51.1% ± 11.8%), rupatadine (55.3% ± 6.6%), and desloratadine (59.8% ± 6.4%), but not levocetirizine (85.4% ± 8.0%). Levocetirizine is expected to have a high antihistamine effect on horses."

Journal • Allergy • Dermatology • Immunology • Urticaria